BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 15871845)

  • 1. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
    Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
    Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
    Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glibenclamide on postprandial coagulation activation.
    Ioannidis I; Tsoukala C; Panayotopoulou C; Skrapari I; Maglara E; Anastasopoulou Y; Mandalaki T; Katsilambros N
    Nutr Metab Cardiovasc Dis; 1999 Aug; 9(4):204-7. PubMed ID: 10614063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK; Sibal L; Ashwell SG; Home PD
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
    Bell PM; Cuthbertson J; Patterson S; O'Harte FP
    Diabetes Res Clin Pract; 2011 Mar; 91(3):e68-70. PubMed ID: 21194775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.
    Morita Y; Ueno T; Sasaki N; Tateishi Y; Nagata E; Kage M; Sata M
    Hepatogastroenterology; 2005; 52(65):1338-43. PubMed ID: 16201069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
    Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
    Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
    Luzio SD; Anderson DM; Owens DR
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.
    Bladbjerg EM; Henriksen JE; Akram S; Gram J
    Diabetes Obes Metab; 2012 May; 14(5):447-53. PubMed ID: 22151836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
    Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
    Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
    Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
    Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.